UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )
Transkaryotic Therapies, Inc.
-------------------------------------------------------
(Name of issuer)
Common Stock
-------------------------------------------------------
(Title of class of securities)
893735100
-------------------------------------------------------
(CUSIP number)
November 13, 2000
-------------------------------------------------------
(Date of Event which requires filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
schedule is filed:
( ) Rule 13d-1(b)
(X) Rule 13d-1(c)
( ) Rule 13d-1(d)
<PAGE>
------------------- -----------------
CUSIP No. 893735100 13G Page 2 of 8 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Deutsche Bank A.G.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ( )
(b) ( )
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
--------------------------------------------------------------------------------
NUMBER OF SHARES 5 SOLE VOTING POWER
BENEFICIALLY
OWNED BY EACH 0
REPORTING -----------------------------------------------------------
PERSON WITH 6 SHARED VOTING POWER
1,661,000
-----------------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
-----------------------------------------------------------
8 SHARED DISPOSITIVE POWER
1,661,000
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,661,000*
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES ( )
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.3%**
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
HC, BK, CO
--------------------------------------------------------------------------------
* Included in this figure are the securities reported by Deutsche Fonds
Holding GmbH on the following cover page.
** Included in this percentage are the percentages of securities reported by
Deutsche Fonds Holding GmbH on the following cover page.
<PAGE>
------------------- -----------------
CUSIP No. 893735100 13G Page 3 of 8 Pages
------------------- -----------------
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Deutsche Fonds Holding GmbH
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ( )
(b) ( )
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Federal Republic of Germany
--------------------------------------------------------------------------------
NUMBER OF SHARES 5 SOLE VOTING POWER
BENEFICIALLY
OWNED BY EACH 0
REPORTING -----------------------------------------------------
PERSON WITH 6 SHARED VOTING POWER
1,661,000
-----------------------------------------------------
7 SOLE DISPOSITIVE POWER
0
-----------------------------------------------------
8 SHARED DISPOSITIVE POWER
1,661,000
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,661,000
--------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES ( )
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.3%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
HC
--------------------------------------------------------------------------------
<PAGE>
Item 1(a). Name of Issuer:
Transkaryotic Therapies, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
The address of the Issuer's principal executive offices is 195 Albany
Street, Cambridge, MA 02139.
Item 2(a). Name of Person Filing:
This statement is filed on behalf of Deutsche Bank AG ("DBAG") and
Deutsche Funds Holding GmbH ("DWS Group" and together with DBAG, the "Reporting
Persons").
Item 2(b). Address of Principal Business Office or, if none, Residence:
The principal place of business of DBAG is Taunusanlage 12, D-60325,
Frankfurt am Main, Federal Republic of Germany.
The principal place of business of DWS Group is Feldbergstrasse 22,
60323 Frankfurt, Federal Republic of Germany.
Item 2(c). Citizenship:
The citizenship of the Reporting Persons is set forth on the
applicable cover page.
Item 2(d). Title of Class of Securities:
The title of the securities is common stock (the "Common Stock").
Item 2(e). CUSIP Number:
The CUSIP number of the Common Stock is set forth on each cover page.
Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or
(c), check whether the person filing is a:
(a) ( ) Broker or dealer registered under section 15 of the Act;
(b) ( ) Bank as defined in section 3(a)(6) of the Act;
(c) ( ) Insurance Company as defined in section 3(a)(19) of the Act;
(d) ( ) Investment Company registered under section 8 of the
Investment Company Act of 1940;
(e) ( ) An investment adviser in accordance with Rule 13d-1
(b)(1)(ii)(E);
(f) ( ) An employee benefit plan, or endowment fund in accordance
with Rule 13d-1 (b)(1)(ii)(F);
(g) ( ) A parent holding company or control person in accordance
with Rule 13d-1 (b)(1)(ii)(G);
(h) ( ) A savings association as defined in section 3(b) of the
Federal Deposit Insurance Act;
(i) ( ) A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940;
(j) ( ) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
If this statement is filed pursuant to Rule 13d-1 (c), check this box.
(X)
Item4. Ownership.
(a) Amount beneficially owned:
Each of the Reporting Persons owns the amount of the Common Stock as
set forth on the applicable cover page.
(b) Percent of class:
Each of the Reporting Persons owns the percentage of the Common Stock
as set forth on the applicable cover page.
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote:
Each of the Reporting Persons has the sole power to vote or
direct the vote of the Common Stock as set forth on the applicable
cover page.
(ii) shared power to vote or to direct the vote:
Each of the Reporting Persons has the shared power to vote or
direct the vote of the Common Stock as set forth on the applicable
cover page.
(iii) sole power to dispose or to direct the disposition of:
Each of the Reporting Persons has the sole power to dispose or
direct the disposition of the Common Stock as set forth on the
applicable cover page.
(iv) shared power to dispose or to direct the disposition of:
Each of the Reporting Persons has the shared power to dispose or
direct the disposition of the Common Stock as set forth on the
applicable cover page.
Item 5. Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Investment management clients of each of the Reporting Persons have
the ultimate right to any dividends from Common Stock and the proceeds from the
sale of Common Stock.
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company.
The following are subsidiaries of DBAG and DWS Group which hold Common
Stock included in the figures on the cover pages: Deutsche Gesellschaft fur
Wertpapiersparen mbh, Deutsche Vermogensbildungsgesellschaft mbh and DWS
Investment Management S.A. Luxemburg.
Item 8. Identification and Classification of Members of the Group.
Not applicable.
Item 9. Notice of Dissolution of Group.
Not applicable.
Item 10. Certification.
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: November 22, 2000
DEUTSCHE BANK AG
By: /s/Dr. Dieter Eisele
---------------------------------
Name: Dr. Dieter Eisele
Title: Group Head of Compliance
By: /s/Christoph Kirschhofer
---------------------------------
Name: Christoph Kirschhofer
Title: Director
<PAGE>
EXHIBIT 1
Consent of Deutsche Fonds Holding GmbH
The undersigned agrees that the Schedule 13G executed by Deutsche Bank
AG to which this statement is attached as an exhibit is filed on behalf of
Deutsche Bank AG and Deutsche Fonds Holding GmbH pursuant to Rule 13d-1(k)(1) of
the Securities Exchange Act of 1934.
Dated: November 22, 2000
DEUTSCHE FONDS HOLDING GMBH
By: /s/Gerhard Seifried
-----------------------------------
Name: Gerhard Seifried
Title: Head of Fund Administration
By: /s/Ralf Ring
-----------------------------------
Name: Ralf Ring
Title: Compliance Officer
